Gynaekologisches Zentrum Bonn

Bonn 15 trials 3 recruiting

15 Registered trials

3 Currently recruiting

Organisation

Gynaekologisches Zentrum Bonn

Location

Bonn, Germany

Identifier

ORG-100041413

Address

Friedensplatz 16, Zentrum, 53111, Germany

Departments

-
Gynäkologisches Zentrum Bonn
Gynäkologisches Zentrum Bonn Friedensplatz
Gynecology
Medical oncology
N/A
NA
Oncology
Praxis Dr. Kurbacher
Studien

Clinical trials at this site (15)

Search interface

HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting

2025-521040-37-00 HER2-positive early breast cancer 5 2025-11-26
An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negat… Recruiting

2024-519913-76-00 PDL1-negative metastatic triple-negative breast cancer 4 2025-12-09
Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced… Recruiting

2024-519871-24-00 Breast cancer 10 2025-11-11
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A study to learn more about how well elinzanetant works and how safe it is compared to placebo for the treatment of hot flashes caused by an… Ended

2023-508265-33-00 Vasomotor symptoms caused by adjuvant endocrine therapy 5 2022-10-13
A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer (… Ended

2023-509260-25-00 Locally Recurrent Inoperable or Metastatic Triple-negat 5 2022-07-12
Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer wit… Ended

2024-511209-49-00 Patients with hormone receptor positive HER2 negative l 6 2022-04-26
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended

2023-503990-39-00 Estrogen Receptor-Positive, HER-2 negative Advanced Bre 5 2021-09-30
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… Ended

2023-503568-18-00 Early human epidermal growth factor receptor 2 (HER2) p 5 2021-04-13
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 ER+/HER2- Breast Cancer 5 2018-12-27
A multicentre, single arm trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 1… Ended

2022-502023-21-00 Prevention of pregnancy 5 2023-07-12
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended

2022-501382-49-00 Triple Negative Breast Cancer (TNBC) 5 2017-03-07